Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

ABSTRACT:

Purpose

The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer.

Experimental design

Outcomes of patients who were referred for treatment on phase I clinical trials at The University of Texas MD Anderson Cancer Center (Houston, TX) from March 2011 to January 2012 were compared between those who had received targeted therapy and those for whom no targeted therapy was available. Two-month landmark analyses for overall and progression-free survival (PFS) combining previously published and validation cohort patient data were performed.

Results

In patients with one alteration, matched therapy (n = 143)

SUBMITTER: Tsimberidou AM 

PROVIDER: S-EPMC4518867 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature